Masimo Co. (NASDAQ:MASI) Receives $194.80 Average PT from Analysts

Shares of Masimo Co. (NASDAQ:MASI) have been given an average recommendation of “Moderate Buy” by the six ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $194.80.

MASI has been the topic of a number of recent analyst reports. Wells Fargo & Company increased their price target on shares of Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Raymond James increased their target price on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. Piper Sandler lifted their target price on Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research report on Thursday.

Masimo Stock Up 1.6 %

MASI stock opened at $153.90 on Friday. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The business has a 50 day moving average of $170.60 and a 200 day moving average of $164.48. Masimo has a twelve month low of $101.61 and a twelve month high of $194.88. The firm has a market cap of $8.32 billion, a PE ratio of 106.14 and a beta of 1.28.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. On average, research analysts forecast that Masimo will post 4.1 EPS for the current fiscal year.

Insider Transactions at Masimo

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of the firm’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the transaction, the director now directly owns 16,581 shares of the company’s stock, valued at approximately $2,754,601.53. This trade represents a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Bilal Muhsin sold 30,000 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the sale, the chief operating officer now owns 24,172 shares of the company’s stock, valued at approximately $4,048,568.28. This represents a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 9.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of MASI. Jones Financial Companies Lllp purchased a new position in shares of Masimo during the 4th quarter valued at about $27,000. UMB Bank n.a. raised its stake in Masimo by 180.9% during the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 123 shares during the period. Trust Co. of Vermont purchased a new position in Masimo during the fourth quarter valued at approximately $33,000. Blue Trust Inc. boosted its position in shares of Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 71 shares during the period. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 64 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.